Skip to content
Lilly2980 80mg

Drawing based on the label description. No photo yet.

“80 mg: blue opaque capsule imprinted with "Lilly", "2980" and "80 mg" in black ink”

Lilly 2980 80mg pill

Pill with imprint Lilly 2980 80mg is blue, capsule, 22 mm and has been identified as Selpercatinib 80 mg. It is used for lung cancer and thyroid neoplasms. It is supplied by Eli Lilly and Company.

Selpercatinib 80 mg

Imprint
Lilly 2980 80mg
Strength
80 mg
Used for
Lung cancer and thyroid neoplasms
Color
Blue
Shape
Capsule / oblong
Size
22 mm
Score
No score line
Form
Capsule
Manufacturer
Eli Lilly and Company
Drug class
Cancer medicine (kinase inhibitor)
NDC
0002-2980, 0002-2980-60, 0002-2980-26

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Selpercatinib pills and guides

What is Selpercatinib used for?

Selpercatinib is used for lung cancer and thyroid neoplasms.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

RET Fusion-Positive Non-Small Cell Lung Cancer

RETEVMO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.

RET-Mutant Medullary Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.

RET Fusion-Positive Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Other RET Fusion-Positive Solid Tumors

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

From the FDA-approved label on DailyMed (published Sep 14, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows Lilly 2980 80mg. The parts can be split between the two sides, so turn the pill over and check both.
  • It is blue, capsule, 22 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Retevmo.

Ingredients

Active: Selpercatinib

Inactive: Microcrystalline Cellulose, Silicon Dioxide, Gelatin, Unspecified, Titanium Dioxide, Fd&c Blue No. 1, Shellac, Alcohol, Isopropyl Alcohol, Butyl Alcohol, Propylene Glycol, Water, Ammonia, Potassium Hydroxide, Ferrosoferric Oxide

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Selpercatinib pills